VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

Core Insights - VolitionRx Limited is preparing a reimbursement submission for its Nu.Q® Cancer assays in France, supported by the Hospices Civils de Lyon, aiming for clinical certification of the test [1][2][3] Group 1: Company Developments - The reimbursement submission is expected to be completed by the end of the current quarter under the "Innovative Procedures Outside the Nomenclature" framework, with a determination of eligibility for reimbursement coverage anticipated within five months [2][3] - VolitionRx aims to introduce the Nu.Q® test into routine clinical use in France by the fourth quarter of 2026, marking a significant milestone in the commercialization of its cancer diagnostics [3] Group 2: Clinical and Market Impact - There are approximately 50,000 new lung cancer diagnoses annually in France, with a five-year prevalence of around 65,000 cases, indicating a substantial market opportunity for the Nu.Q® Cancer assays [3] - The Nu.Q® test is expected to enhance precision in treatment selection and monitoring for lung cancer patients, providing valuable information regarding survival and progression-free survival [2][3] Group 3: Collaborations and Support - The collaboration with Hospices Civils de Lyon is crucial for the submission process, as they are France's second-largest university hospital system, which will facilitate the integration of the Nu.Q® test into clinical practice [2][5] - The support from HCL underscores the strong scientific and clinical evidence developed over several years to validate the use of Nu.Q® in cancer management [2]